Kathleen Kerrigan, DO
Hematology & Oncology · Columbus, OHNPI 1457779035
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,934 of the $47,412 with a category attached, or 77.9%. Genentech USA, Inc. accounts for 74.5% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $23,089, more than ten times the $146 reported in 2022.
Across 72 payments — averaging $658.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$35K
- Sanofi$7K
- AstraZeneca$3K
- EMD Serono, Inc.$2K
- Beigene, Ltd.$560
- E.r. Squibb & Sons, L.L.C.$258
- plus $353 from 6 others
Across 124 payments — averaging $6202.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$548K
- Janssen Research & Development, LLC$166K
- AstraZeneca$56K
What the payments were for
- Consulting fees$4,3779%
- Speaking & faculty fees$36,93478%
- Travel & lodging$3,8848%
- Food & beverage$2,2175%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 43 | $35,333 |
| Sanofi | 9 | $6,521 |
| AstraZeneca | 8 | $2,625 |
| EMD Serono, Inc. | 1 | $1,762 |
| Beigene, Ltd. | 1 | $560 |
| E.r. Squibb & Sons, L.L.C. | 3 | $258 |
| Regeneron Healthcare Solutions, Inc. | 2 | $219 |
| Genentech, Inc. | 1 | $54 |
| Myovant Sciences Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Merck | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$47,412 in reported general payments places this provider in the 85th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MekinistTrametinib Dimethyl Sulfoxide | 30 | $461,986 |
| TafinlarDabrafenib Mesylate | 31 | $440,885 |
| LenvimaLenvatinib Mesylate | 14 | $343,818 |
| RetevmoSelpercatinib | 11 | $255,397 |
| EliquisApixaban | 34 | $21,923 |
| XareltoRivaroxaban | 20 | $14,851 |
| Levothyroxine Sodium | 117 | $1,271 |
| Prochlorperazine Maleate | 47 | $675 |
| Oxycodone Hcl | 22 | $609 |
| Olanzapine | 27 | $476 |
| Ondansetron Hcl | 59 | $396 |
| Dexamethasone | 20 | $278 |
| Potassium Chloride | 19 | $244 |
| Lidocaine Hcl ViscousLidocaine Hcl | 15 | $144 |
| Lorazepam | 17 | $64 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Columbus
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Sameh MikhailColumbus$135K
- Erin BertinoColumbus$73K
- Mark KnappColumbus$67K
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Saulius GirniusMontgomery$707K
- Ronald BukowskiCleveland$594K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.